Venus Medtech Enters North American Market

Food and Healthcare Press Releases Thursday June 14, 2018 12:19
HANGZHOU, China and VANCOUVER, Canada--14 Jun--PRNewswire/InfoQuest
  • First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada

On June 12, 2018, St Paul 's Hospital in Vancouver, Canada successfully completed two cases of VenusP-Valve self-expanding pulmonary valve implantation. This is the first appearance of Venus Medtech's transcatheter valve products in North America. The pace of internationalization continues to move forward.

Although surgical treatment of congenital heart disease has evolved dramatically in recent decades, operations involving the right ventricular outflow tract (RVOT) can still result in chronic pulmonary regurgitation, necessitating either surgical or percutaneous pulmonary valve implantation.

Percutaneous pulmonary valve implantation has emerged as a successful alternative to surgical valve implantation in such patients. However, the currently available balloon-expandable percutaneous valves are suitable only for outflow tracts reconstructed with cylindrical surgical tubes. Treatment of pulmonary regurgitation in the setting of prior RVOT patch augmentation has traditionally been limited to surgical intervention. This is mainly due to the limited available sizes of balloon-expandable valves relative to often severely dilated outflow tracts.

The self-expanding VenusP-valve has been developed specifically for percutaneous use in the native RVOTs to overcome the challenge of the larger outflow tracts and can fulfill the needs of more than 85% of patients who are keen to avoid sternotomy and cardiopulmonary bypass during traditional valve replacement surgery.

The procedure was performed on two patients who were previously treated with surgical patch correction for tetralogy of Fallot. Dr. Ronald G Carere and Dr. Mounir Riahi (St Paul 's Hospital, Canada) agreed with Dr. Shakeel Qureshi (Evelina Children's Hospital, Great Britain) and Dr. Gejun Zhang (Fuwai Hospital, China) that these patients were more at risk of reventriculotomy, and the currently available transcatheter pulmonary valve products were not suitable for these cases. The expert team selected the VenusP-Valve as the most suitable device to serve this unmet need. Dr. Carere said: "The VenusP-Valve performed beautifully and has a simple to operate delivery system. We are very happy to have this device in our center, and we look forward to having it widely available in Canada."

In recent years, the transcatheter artificial heart valve systems developed by Venus Medtech have been attracting more and more attention worldwide. The upcoming VenusP-Valve global multi-center clinical trial has received more than 200 applications from nearly 30 countries worldwide. The VenusP-Valve was first implanted in Canada, marking the official entry into the North American market, and the company is expected to officially launch the FDA clinical trial in 2019.

Photo - https://photos.prnasia.com/prnh/20180614/2162324-1
Caption: First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada

Latest Press Release

Menicon Announces Launch of Menicon Bloom Myopia Control Management System

- Launch Features Initial Introduction of Menicon Bloom Night, First and Only CE-approved Orthokeratology Contact Lens in Europe for Myopia Control - Menicon Co., Ltd. announced on May 24 the launch of the Menicon Bloom Myopia Control Management System,...

Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event

- Global health leaders covered biomanufacturing and neglected tropical diseases (NTDs) during 72nd World Health Assembly - Event focused on innovative science and technology-based solutions to increase access to medicines and biologics Merck, a...

Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology

Menarini Ricerche will present three different projects related to the compounds in clinical development SEL24/MEN1703, MEN1611 and MEN1309/OBT076 at the ASCO Annual Meeting 2019 in Chicago. During the poster session "Breast Cancer – Metastatic"...

Surgical Specialties Corporation Launches Caliber Ophthalmics Division to Focus on Global Growth of Ophthalmic Surgical Procedures

Surgical Specialties Corporation (SSC) announced today the launch of Caliber Ophthalmics, a new business division. Caliber Ophthalmics combines SSC's Sharpoint(TM) brand, which has earned a trusted reputation serving ophthalmic surgeons for over 50...

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

Ori Yehudai: "I took a company worth $3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants, and...

Related Topics